Close
Nordic 9Nordic 9

Digitalis Ventures (investor - None)

United States digitalisventures.com
See something wrong or missing? Let us know
Offices:New York
Average round investment:30.73M USD
Average number per year:1.0
Distribution: 2025 (1)2023 (1)2021 (1)2019 (1)
Portfolio companies: Switzerland Astra TherapeuticsUnited Kingdom Ascend Gene & Cell TherapiesUnited Kingdom PetMedix
Mostly invests in: United Kingdom United Kingdom (3) Biotech (4)
See the entire list

Showing 3 of 4 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Digitalis Ventures

Name Criteria
United States Acorn Bioventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Hong Kong CR-CP Life Science Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States KB Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Rosetta Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Supermoon Capitals
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Mayo Clinic
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Rick Klausner
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France BOLD - Business Opportunities for L'Oréal Development
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan UTokyo IPC
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top